Insight Molecular Diagnostics
IMDX
54 hedge funds and large institutions have $39.8M invested in Insight Molecular Diagnostics in 2019 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 14 increasing their positions, 15 reducing their positions, and 14 closing their positions.
178% more call options, than puts
Call options by funds: $25K | Put options by funds: $9K
29% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 14
8% more funds holding
Funds holding: 50 → 54 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.02% less ownership
Funds ownership: 1.55% → 1.54% (-0.02%)
7% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 15
38% less capital invested
Capital invested by funds: $63.7M → $39.8M (-$23.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.94M |
| 2 |
State Street
Boston,
Massachusetts
|
+$1.46M |
| 3 |
MS
Maven Securities
St Helier,
Jersey
|
+$896K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$651K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$533K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$5.09M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$2.82M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$717K |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
-$670K |
| 5 |
Millennium Management
New York
|
-$579K |
IMDX Hedge Fund Activity: Q2 2019 in Review
54 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q2 2019, worth a combined $39.8M — down 38% from $63.7M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new IMDX positions and 14 closed out — a net gain of 4 holders — while 14 added to existing stakes and 15 trimmed.
The largest buyer was BlackRock, adding an estimated $5.94M. The largest seller was RTW Investments, exiting entirely with an estimated $5.09M sold.
- 54 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q2 2019, up from 50 in Q1 2019.
- Funds reported $39.8M of Insight Molecular Diagnostics stock for Q2 2019, down 38% quarter-over-quarter.
- 18 funds opened new Insight Molecular Diagnostics positions in Q2 2019 and 14 closed out, a net change of +4 holders.
- The largest Insight Molecular Diagnostics buyer in Q2 2019 was BlackRock, an estimated $5.94M added.
- The largest Insight Molecular Diagnostics seller in Q2 2019 was RTW Investments, an estimated $5.09M sold.
Based on aggregated 13F filings for Q2 2019.